After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing pact, ...
Mere days after announcing that trials for its lead IL-15 asset have been halted over poor data, Sotio Biotech has unveiled plans to delve deeper into antibody-drug conjugates (ADCs) courtesy of deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results